Member Info for Muck165

I called Bioserv today to get bulk quotes for Healgen and Affidx. This was the reply I have just had in writing

"Great talking on the phone earlier

Please find attached a discounted quote. For the Avacta we charged £125 per box instead of £175/box. The Healgen tests (self tests) were charged at £2.50/test instead of £10/test.

In regards to Omicron detection. The Healgen test detects Omicron. For Avacta, this is what my manager had to say

"Regarding the sensitivity to Omicron. It is highly likely there will be no change to the sensitivity or specificity of the Affidx test. Its actually more likely that the test will improve because of the increased binding affinity of the Omicron spike protein to the ACE2 protein receptor. You'll be interested to know that Affidx has an increased sensitivity to the Delta variant compared to wild type and other variants at the time of testing. All been said, this need to be tested to give 10% confidence levels. Avacta are currently performing analysis with clinical samples to assess performance""

Just posting for info. Cant say that Bioserv have filled me with confidence, but its interesting they were willing to talk about bulk orders for Affidx (I was looking for 1200 tests) when apparently it should have been withdrawn from sale. Clearly only AVCT can say, through an RNS, whether Affidx does in fact detect Omicron.

I called Bioserv today to get bulk quotes for Healgen and Affidx. This was the reply I have just had in writing

"Great talking on the phone earlier

Please find attached a discounted quote. For the Avacta we charged £125 per box instead of £175/box. The Healgen tests (self tests) were charged at £2.50/test instead of £10/test.

In regards to Omicron detection. The Healgen test detects Omicron. For Avacta, this is what my manager had to say

"Regarding the sensitivity to Omicron. It is highly likely there will be no change to the sensitivity or specificity of the Affidx test. Its actually more likely that the test will improve because of the increased binding affinity of the Omicron spike protein to the ACE2 protein receptor. You'll be interested to know that Affidx has an increased sensitivity to the Delta variant compared to wild type and other variants at the time of testing. All been said, this need to be tested to give 10% confidence levels. Avacta are currently performing analysis with clinical samples to assess performance""

Just posting for info. Cant say that Bioserv have filled me with confidence, but its interesting they were willing to talk about bulk orders for Affidx (I was looking for 1200 tests) when apparently it should have been withdrawn from sale. Clearly only AVCT can say, through an RNS, whether Affidx does in fact detect Omicron.

Who says Muck’s common..:)

For those that may have missed it, Igas posted this on their site last week.

https://www.igasplc.com/media/47536/net-zero-rise.pdf

Here’s a bit more on “Net zero RISE”

https://www.ncl.ac.uk/business-and-partnerships/expert-solutions/collaborative-research/net-zero-rise/

https://agiletestservices.com/

And there you have it -Powered by Saturn Pass, Medusa 19’s sister company

No guarantee this will be for AffiDx/Meduflow, but can’t see it being anything else given that Medusa’s only other tes is Ann antibody not an antigen test.

Great spot livedataccount! Powered by Saturn Pass

https://agiletestservices.com/

I picked up free NHS tests from Boots this morning - Orientgene.

Basically the same set up as Flowflex that I’d been given before, except the nozzle isn’t attached to the extraction tube. Instead it’s separate, and you have to put it in. All very simple until I came to dispense the drops onto the cassette. Nothing came out, so I squeezed a little harder and the nozzle popped out followed by all the contents of the tube!

Not a great first impression of the test!

Meeting with Bethell was 11 May THIS year.

I’ve been posting a lot about Agile on the AVCT board over the last few weeks.

It was set up last year by Peter Whitehurst, at roughly the same time as he set up Medusa 19 Life Sciences. It always seemed odd because this is a guy with real pedigree, having been part of an exec team that sold its business for £2.5bn in 2010, and then was CEO of Arcis Bio for 10 years (corporate brokers to which are Zeus Capital, ie Richard Hughes of M19). Why leave all that behind to set up a couple of start ups unless you had backing and a belief you’d succeed?

Agile have built their website and been advertising that day 2 LFT testing is coming soon. Of particular note is that Agile, this little start up, joined the likes of Abbott and Roche in 11May meeting with Bethell last year to discuss new diagnostic testing legislation. Why would a little company incorporated just a year before, and with no apparent trading history, be invited to such a meeting?!

I firmly believe there is far more going on behind the scenes with M19/AffiDx, and that Agile and Whitehurst are in the thick of it.

Well who knows Muller12!

What we can say is that Peter Whitehurst has some pedigree, having been part of the Executive team at SSL (Durex, Scholl) which sold out to Reckitt Benckiser in 2010 for £2.5bn, before joining Arcis as CEO. He ran Arcis for 10 years before taking his next big career move……setting up Agile and M19 LS? Why would a man of that calibre do that? Presumably because he expects to have the clout behind him to get into governmental meetings!

Just to note, Zeus appear to have been involved with Arcis for some time.

https://www.thebusinessdesk.com/northwest/news/99907-zeus-advises-arcis-on-funding-deal

https://en.wikipedia.org/wiki/SSL_International

Another curiosity…

Agile Life Sciences was included in a meeting on 11 May with Bethell “to discuss upcoming legislation to validate Covid 19 tests on the market”.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1027379/Q1_2021_Ministers_Meetings.csv/preview

Why would a company, incorporated just a year before that meeting, and which had ostensibly done nothing prince incorporation, be included in that meeting with the likes of Abbott, Roche, BIVDA, ABHI, Randox etc?

I may be banging on about something that doesn’t exist, but it’s just really odd and I would not be in the slightest bit surprised to find out that Agile, M19 LS, Arcis etc are in some way involved with AffiDx/Meduflow marketing and distribution.

*vax

Don’t know if this has already been posted - apologies if so.

https://www.medrxiv.org/content/10.1101/2021.12.08.21267353v1.full

It’s a research paper published 8/12, funded by the DHSC and the Welsh Govt, and authored by top academics including Peto and Bell.

“ In summary, prior infection significantly boosts antibody responses after a single ChAdOx1, BNT162b2, or mRNA-1273 vaccination, producing higher peak levels and longer half-lives, comparable or even better to that obtained from two vaccinations in those without prior infection. Based on the positivity threshold and previously reported correlates of protection, those with prior infection could be protected from infection for >1 year after a single vaccination. While recent studies show that a third vaccination boosts antibody responses31 and provides better protection against infection than two vaccinations,32 and two vaccinations plus prior infection provides better protection against re-infection than prior infection alone,8 a large part of the global population did not yet have the chance to get their first vaccination due to limited vaccine supplies. These results could inform vaccine strategies, providing an evidence-base to optimise population immunity in the context of resource limitations, while international SARS-CoV-2 immunisation programmes are scaled up and secured.”

Put another way, vaccination programs in poorer countries could be optimised by understanding prior infection and targeting vaccine measures accordingly. ABDX and ODX have been saying this for ages, and here we now have a research paper with serious academic clout back it up.

Don’t know if this has already been posted - apologies if so.

https://www.medrxiv.org/content/10.1101/2021.12.08.21267353v1.full

It’s a research paper published 8/12, funded by the DHSC and the Welsh Govt, and authored by top academics including Peto and Bell.

“ In summary, prior infection significantly boosts antibody responses after a single ChAdOx1, BNT162b2, or mRNA-1273 vaccination, producing higher peak levels and longer half-lives, comparable or even better to that obtained from two vaccinations in those without prior infection. Based on the positivity threshold and previously reported correlates of protection, those with prior infection could be protected from infection for >1 year after a single vaccination. While recent studies show that a third vaccination boosts antibody responses31 and provides better protection against infection than two vaccinations,32 and two vaccinations plus prior infection provides better protection against re-infection than prior infection alone,8 a large part of the global population did not yet have the chance to get their first vaccination due to limited vaccine supplies. These results could inform vaccine strategies, providing an evidence-base to optimise population immunity in the context of resource limitations, while international SARS-CoV-2 immunisation programmes are scaled up and secured.”

Put another way, vaccination programs in poorer countries could be optimised by understanding prior infection and targeting vaccine measures accordingly. ABDX and ODX have been saying this for ages, and here we now have a research paper with serious academic clout back it up.

Pinched from the AVCT board courtesy of blownitalready

https://clpmag.com/diagnostic-technologies/clinical-laboratories-16-industry-predictions-for-2022/

An interesting piece. ABDX seem very well positioned to benefit.

Timster - possibly people selling here to trade ODX on the dip?

Yep - just the latest U.K. company to get screwed by the U.K. govt.

For info, couple of responses from Maggie Throup today re LFT’s in the U.K.

https://questions-statements.parliament.uk/written-questions/detail/2021-12-01/85387

https://questions-statements.parliament.uk/written-questions/detail/2021-11-30/84297

Just one other curiosity here for info..

Medusa 19 Life Sciences Ltd, ie the company that Peter Whitehurst set up last year, has a device registered with the MRHA. It seems to be an antibody test and so I wonder if it’s the Medusa 19 RSPT? There are no other Medusa 19 companies with a registration.

For info and probably an irrelevance. But it’s somewhat odd and curious.

https://aic.mhra.gov.uk/era/pdr.nsf/Search?SearchView&Query=/era/pdr.nsf/Search?SearchView&Query=%5BManName%5DContains(%22Medusa%22)&SearchOrder=4

Just a question. Vatic is the only other spike test I know, and they make this claim on LinkedIn;

“Because our test mimics a human cell, we are in fact seeing the more dominant strains mutate towards better binding affinity between the cell invasion mechanism of the virus and the surface of a human cell, precisely because it plays a role in making the virus more effective at entering cells, which impacts on its replication capabilities and thereby infectiousness”.

“The KnowNow Spike Test uses the same principle as the viral entry on a lateral flow assay platform to detect the virus. In our case as the virus mutates and becomes more infectious, our test should get more sensitive”

I’ll just own up and admit I don’t understand this. I would have thought they must have an assay which attaches somewhere in the spike like us, so why do they seem unconcerned with spike variants? Or is it BS?

Thanks for any help.